A S X A N N O U N C E M E N T Results of Annual General Meeting Wednesday, 18 November 2026 Ceryvyn Therapeutics Limited (ASX:CYV) (“Ceryvyn” or the “Company”) advises that in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), the results of the...
Ceryvyn Therapeutics: Results of AGM
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Ceryvyn Therapeutics Limited has announced the results of its Annual General Meeting, where all resolutions were carried by the requisite majority. The announcement complies with Listing Rule requirements and includes details of the resolutions voted on by shareholders. Ceryvyn is focused on developing therapies for serious diseases, particularly lymphangioleiomyomatosis, with its lead program targeting key proteins involved in disease progression.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/results-of-agm-216
Release
Ceryvyn Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Ceryvyn Therapeutics
- Investor Presentation
- Quarterly Activities/Appendix 4C Cash Flow Report
- Change of Auditor
- Notice of Annual General Meeting/Proxy Form
- Change in substantial holding
Later from Ceryvyn Therapeutics
All Ceryvyn Therapeutics news releasesFollow Ceryvyn Therapeutics into a list and get an email when it puts out news.
Follow Ceryvyn Therapeutics